Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27801224 | 0.87 | LOX (0.32) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL4308442 | 0.86 | GABRA1 (0.31) | GABRA1GABRA5KMT2AMEN1HTT | |
| SCHEMBL4313333 | 0.81 | BACE1 (0.38) | CYP3A4 | |
| SCHEMBL4306191 | 0.79 | MAPT (0.40) | HPGDKMT2AMEN1HTTL3MBTL1 | |
| SCHEMBL4309267 | 0.79 | MEN1 (0.34) | ACACBHPGDKMT2ACYP1A2CYP2C9 | |
| SCHEMBL4309746 | 0.78 | LMNA (0.32) | ACACBHPGDKMT2ACYP1A2CYP2C9 | |
| SCHEMBL4304316 | 0.77 | ACACB (0.41) | ACACBCYP3A4L3MBTL1SMN1; SMN2 | |
| SCHEMBL4306215 | 0.77 | L3MBTL1 (0.35) | ACACBHPGDKMT2ACYP1A2CYP2C9 | |
| SCHEMBL6180348 | 0.75 | GABRA1 (0.36) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL15108891 | 0.75 | NTRK1 (0.42) | HPGDKMT2AMEN1KCNH2GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101641335-A | Amino-5-[substituted-4-(difluoromethoxy)phenyl]-5- phenylimidazolone compounds as ss-secretase inhibitors | WYETH CORP US | 2010-02-03 | — | — | CN | disclosed |
| EP-2137161-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008115552-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, APP | GABRA1 1520/4885GABRA5 547/4885GABRG2 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.